Dr. Yong Cang, CSO and Co-Founder of Degron Therapeutics, who has dedicated his research to the TPD field for over 20 years, will attend this event as a speaker.
The Targeted Protein Degradation (TPD) Assay Development & Screening Summit, the first industry-dedicated conference for those seeking to improve their assay development and screening capabilities to fast-track protein degrader R&D, will be held on December 6 - 8, 2022 in San Diego, CA.
Dr. Yong Cang, CSO and Co-Founder of Degron Therapeutics, who has dedicated his research to the TPD field for over 20 years, will attend this event as a speaker and his presentation title is “Screening Rationally Designed MGD Libraries to Unravel Degradable Proteins”. He will also co-chair with Dr. Torren Finkel from University of Pittsburg the discussion panel “How to Design & Optimize the Screening Strategy Specifically for Molecular Glues”.
Click the link to know more https://tpd-assays-screening.com/
Targeted Protein Degradation (TPD) has emerged as an exciting new modality in small molecule drug discovery with more degraders in the clinic than ever before. Despite this, degrader R&D is currently limited by low-throughput screening tools, a lack of robustness and repeatability.
With proof of concept and proof of biology now a reality for TPD, the time has come to evaluate the toolbox to accelerate degrader R&D and address the urgent need for high-throughput screening methods of monitoring TPD that are efficient, robust, sensitive, quantifiable, and reproducible.